Literature DB >> 18195328

Early events in the pathogenesis of epithelial ovarian cancer.

Charles N Landen1, Michael J Birrer, Anil K Sood.   

Abstract

Ovarian carcinogenesis, as in most cancers, involves multiple genetic alterations. A great deal has been learned about proteins and pathways important in the early stages of malignant transformation and metastasis, as derived from studies of individual tumors, microarray data, animal models, and inherited disorders that confer susceptibility. However, a full understanding of the earliest recognizable events in epithelial ovarian carcinogenesis is limited by the lack of a well-defined premalignant state common to all ovarian subtypes and by the paucity of data from early-stage cancers. Evidence suggests that ovarian cancers can progress both through a stepwise mutation process (low-grade pathway) and through greater genetic instability that leads to rapid metastasis without an identifiable precursor lesion (high-grade pathway). In this review, we discuss many of the genetic and molecular disorders in each key process that is altered in cancer cells, and we present a model of ovarian pathogenesis that incorporates the role of tumor cell mutations and factors in the host microenvironment important to tumor initiation and progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195328     DOI: 10.1200/JCO.2006.07.9970

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  176 in total

1.  Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts.

Authors:  Sara Previdi; Anastasia Malek; Veronica Albertini; Cristina Riva; Carlo Capella; Massimo Broggini; Giuseppina M Carbone; Jurgen Rohr; Carlo V Catapano
Journal:  Gynecol Oncol       Date:  2010-05-08       Impact factor: 5.482

2.  Texture analysis applied to second harmonic generation image data for ovarian cancer classification.

Authors:  Bruce L Wen; Molly A Brewer; Oleg Nadiarnykh; James Hocker; Vikas Singh; Thomas R Mackie; Paul J Campagnola
Journal:  J Biomed Opt       Date:  2014-09       Impact factor: 3.170

3.  Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study.

Authors:  Xiaoli Zhang; Bin Xu; Chuanying Sun; Liming Wang; Xia Miao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 4.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

5.  Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Authors:  Stefani N Thomas; Lijun Chen; Yang Liu; Naseruddin Höti; Hui Zhang
Journal:  J Proteome Res       Date:  2017-09-14       Impact factor: 4.466

6.  Epithelial ovarian cancer stem cells-a review.

Authors:  Yueyin Pan; Xudong Huang
Journal:  Int J Clin Exp Med       Date:  2008-06-30

7.  Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Jan Lubinski; Jacek Gronwald; Cezary Cybulski; Rochelle Demsky; Susan L Neuhausen; Charmaine Kim-Sing; Nadine Tung; Susan Friedman; Leigha Senter; Jeffrey Weitzel; Beth Karlan; Pal Moller; Ping Sun; Steven A Narod
Journal:  Int J Cancer       Date:  2014-12-18       Impact factor: 7.396

Review 8.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

Review 9.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

Review 10.  Cancer therapy using natural ligands that target estrogen receptor beta.

Authors:  Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Chin J Nat Med       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.